|
|
|
European Biopharmaceutical Review
|
| Cancer is one of the major killers in the developed world, accounting for over one million deaths in North America and Europe annually. In the US, the annual incidence of cancer is approximately 1,200,000, and the number of people dying of the disease each year is about 500,000 (1). The American Cancer Society estimates that one in three Americans will develop cancer in his or her lifetime. Between 1970 and 1990, the overall five-year survival rate of treated cancer patients improved by about 10 per cent as a result of earlier detection, improved radio- and chemotherapies and, possibly, changes in living habits. However, with the exception of small cell lung carcinoma and breast cancer, improvement in advanced stages has been negligible. Moreover, the lack of specificity of radio- and chemotherapies causes severe side effects. Therefore, new therapies with better efficacy and specificity are needed. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Jean-Pierre Abastado, Vice-President, Scientific Affairs, IDM
Jean-Pierre Abastado is Vice-President in charge of Scientific Affairs at IDM. He is on leave from the CNRS, where he is Research Director. He graduated from the Ecole Polytechnique in 1978 and obtained his PhD in biological sciences from the University of Paris VI in 1986. From 1979 to 1998, he held several positions at the Pasteur Institute (in Paris, France) and NIH (in Bethesda, US). From 1990 to 1998, he managed a group of eight people in the unit of Professor Philippe Kourilsky, specialising in molecular biology and fundamental immunology. Between 1994 and 1998 he was named, on several occasions, an independent expert by the Pasteur Institute, Pasteur-Mérieux Sérums et Vaccins and INSERM. He is the Author of more than 80 scientific publications and of several patent applications in France and the US.
|
|
|
|
|
|
 |
Industry Events |
 |
BioPartnering North America™
26-28 February 2012, Vancouver Convention Centre, Vancouver, BC, Canada
BioPartnering North America 2012 (BPN) in Vancouver, Canada brings together senior executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size from mature to start-up.
More info >> |
|
 |
News and Press Releases |
 |
Kallik’s new approach to asset management delivers long term artwork automisation
Marketing and compliance departments can now have greater control over their assets –from logos and images to labelling copy – and a roadmap to automated artwork generation, thanks to Kallik’s online Asset Repository. It is the most cost-effective way to lay the foundation for future automisation of the artwork and labelling generation. The practice of centralising the content in a web-based asset library and reusing those assets across all marketing and trade communications is saving businesses thousands, if not millions, of pounds.
More info >> |
|
|
